Developing a new antifungal treatment for serious Candida auris infections
Official title: Development and evaluation of a second-generation fungerp for systemic and cutaneous C. auris infection
Funded at Case Western Reserve University · NIH-10977041 · Data updated 2026-11-12
This study is testing a new antifungal medicine called SCY-247 to help people with tough infections caused by a fungus called Candida auris, which is hard to treat with current options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | November 10, 2022 |
| Project end | October 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $648,567 |
| NIH project number | 5R01AI172944-03 |
| Project ID | NIH-10977041 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals, particularly those in healthcare settings, who are at risk of or currently suffering from Candida auris infections.
✕Less likely to help
Patients with infections caused by other non-Candida auris pathogens may not benefit from this research.
What this research studies
This research focuses on creating and testing a new antifungal medication specifically designed to combat infections caused by Candida auris, a dangerous fungus that has shown high resistance to existing treatments. The approach involves developing a second-generation drug, SCY-247, which aims to effectively target both systemic and skin infections. By addressing the unique challenges posed by C. auris, the research seeks to provide a novel therapeutic option for patients suffering from these severe infections. The study will involve laboratory testing and clinical evaluations to assess the drug's safety and effectiveness.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly reduces mortality rates associated with Candida auris infections.
How similar studies have gone: Other research has shown promise in developing new antifungal agents, but this specific approach targeting C. auris is relatively novel.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Ghannoum, Mahmoud a — Case Western Reserve University
- Study coordinator: Ghannoum, Mahmoud a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.